Startupsby GlyphGEn1E Lifesciences
Active · AI platform accelerating therapies for rare & inflammatory diseases.
Why it ranks
How the rank works- went through YCProgram · this site+4
A sum of public facts, not a judgement and not investment advice.
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Active | YCS21 | |
| Other | Active | YCS22 | |
| Other | Active | YCS21 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Active | YCW22 | |
| Other | Active | YCW22 | |
| Other | Active | YCW24 | |
| AI | Active | YCW20 | |
| Gerostate AlphaShared: biotech, disease, novelYC S18InactiveOther | Other | Inactive | YCS18 |
Also from S19 in AI
All of S19About GEn1E Lifesciences
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities, creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital, a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.
- YC batch
- S19 · Summer 2019
- Status, per YC
- Active
- Category
- AI
- Location
- San Francisco, CA, USA
- Checked
- 7h ago
YC tags: Biotech, Healthcare, Drug discovery, AI
Changes seen
Newly tagged AI; no longer tagged Artificial Intelligence.
GEn1E Lifesciences: questions
Which YC batch was GEn1E Lifesciences in?
GEn1E Lifesciences was in Y Combinator's Summer 2019 batch (S19).
Is GEn1E Lifesciences still active?
Y Combinator lists GEn1E Lifesciences as active.
Where is GEn1E Lifesciences based?
GEn1E Lifesciences lists San Francisco, CA, USA as its location on YC's directory.